ClearPoint Neuro, Inc. (CLPT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

ClearPoint Neuro, Inc. (CLPT) Healthcare & Pipeline Overview

ClearPoint Neuro, Inc. develops and commercializes platforms for minimally invasive surgical procedures in the brain, utilizing MRI guidance. The company's ClearPoint system and Neuro Navigation System facilitate precise insertion of electrodes, biopsy needles, and catheters. With strategic collaborations, ClearPoint Neuro aims to enhance neurosurgical outcomes and expand its market presence in the medical device sector.

What Is the Investment Thesis for CLPT?

ClearPoint Neuro, Inc. presents a compelling investment thesis centered on its innovative MRI-guided neurosurgical platform. The company's technology addresses a critical need for more precise and less invasive brain surgery techniques. With a market capitalization of $456M, ClearPoint Neuro operates in a high-growth sector driven by increasing demand for advanced neurosurgical solutions. Key value drivers include expanding adoption of the ClearPoint system for deep brain stimulation, biopsy, and drug delivery applications. Growth catalysts include ongoing collaborations with leading medical institutions and device manufacturers, as well as the potential for new product development and regulatory approvals. However, the company's negative profit margin of -69.1% indicates a need for improved cost management and revenue scaling. Investors should monitor the company's ability to achieve profitability and manage competition in the evolving neurosurgical device market.

Based on FMP financials and quantitative analysis

CLPT Key Highlights

Market capitalization of $456M, reflecting investor valuation of ClearPoint Neuro's growth potential in the neurosurgical device market.

• Gross margin of 61.4%, indicating strong pricing power and efficient cost of goods sold management.
• Beta of 1.18, suggesting that the stock is more volatile than the overall market.
• Strategic collaborations with Boston Scientific Corporation, The Johns Hopkins University, and Koninklijke Philips N.V., enhancing technological capabilities and market reach.
• Focus on minimally invasive surgical procedures in the brain, aligning with the trend towards less invasive medical interventions.

Who Are CLPT's Competitors?

CLPT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CLPT's Key Strengths?

Innovative MRI-guided platform for precise neurosurgery.

• Strategic collaborations with leading medical institutions.
• Strong intellectual property portfolio.
• Focus on minimally invasive procedures.

What Are CLPT's Weaknesses?

Negative profit margin.

• Limited market share compared to larger competitors.
• Reliance on strategic partnerships for growth.
• High operating expenses.

What Could Drive CLPT Stock Higher?

CLPT catalyst: Expansion of clinical applications for the ClearPoint system, including gene therapy and targeted cancer treatments.

• Strategic partnerships with leading medical institutions and device manufacturers to accelerate product development and commercialization.
• Potential regulatory approvals for new ClearPoint system features and applications.
• Increasing adoption of the ClearPoint platform in hospitals and medical centers.

What Are the Key Risks for CLPT?

Financial-distress signal — its Altman Z-Score of -0.23 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 8 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from established medical device companies with greater resources.
• Regulatory hurdles and delays in obtaining approvals for new products.
• Technological obsolescence and the emergence of competing technologies.
• Economic downturn affecting healthcare spending and hospital budgets.
• Dependence on key strategic partnerships for growth and market access.

What Are the Growth Opportunities for CLPT?

• Expansion of ClearPoint System Applications: ClearPoint Neuro can expand the applications of its ClearPoint system beyond deep brain stimulation, biopsy, and drug delivery. This includes exploring new therapeutic areas such as gene therapy and targeted cancer treatments. The market for gene therapy is projected to reach $36 billion by 2031, presenting a significant growth opportunity. By developing specialized tools and protocols for these emerging therapies, ClearPoint Neuro can increase its market share and revenue streams.
• Strategic Partnerships and Collaborations: ClearPoint Neuro can leverage strategic partnerships and collaborations to expand its market reach and technological capabilities. Collaborating with leading medical institutions and device manufacturers can accelerate product development and commercialization. For example, partnering with a major pharmaceutical company to develop a drug delivery system for Alzheimer's disease could open up a significant market opportunity. These partnerships can provide access to new technologies, expertise, and distribution channels.
• Geographic Expansion: ClearPoint Neuro can expand its geographic presence beyond the United States. The European and Asian markets offer significant growth opportunities, driven by increasing healthcare spending and demand for advanced medical technologies. By establishing sales and distribution networks in these regions, ClearPoint Neuro can tap into new customer bases and diversify its revenue streams. This expansion requires careful planning and execution, including regulatory approvals and cultural adaptation.
• Development of Advanced Navigation Systems: ClearPoint Neuro can invest in the development of more advanced navigation systems that integrate artificial intelligence and machine learning. These systems can provide surgeons with real-time guidance and decision support, further enhancing precision and efficiency. The market for surgical navigation systems is projected to reach $1.1 billion by 2028. By developing innovative navigation technologies, ClearPoint Neuro can maintain its competitive edge and attract new customers.
• Focus on Personalized Medicine: ClearPoint Neuro can focus on developing personalized medicine solutions that tailor treatments to individual patient needs. This includes using genetic information and imaging data to optimize drug delivery and surgical planning. The market for personalized medicine is growing rapidly, driven by advancements in genomics and data analytics. By offering personalized solutions, ClearPoint Neuro can differentiate itself from competitors and improve patient outcomes.

What Are CLPT's Competitive Advantages?

• Proprietary MRI-guided platform for minimally invasive neurosurgery.
• Strong intellectual property portfolio protecting key technologies.
• Established relationships with leading medical institutions and device manufacturers.
• High switching costs for customers due to specialized training and infrastructure requirements.

What Does CLPT Do?

ClearPoint Neuro, Inc., founded in 1998 and headquartered in Solana Beach, California, operates as a medical device company focused on developing and commercializing innovative platforms for minimally invasive surgical procedures within the brain. Originally named MRI Interventions, Inc., the company rebranded to ClearPoint Neuro, Inc. in February 2020 to better reflect its core focus. The company's flagship product, the ClearPoint system, enables surgeons to perform procedures under direct, intra-procedural magnetic resonance imaging (MRI) guidance, enhancing precision and minimizing invasiveness. This system facilitates the insertion of deep brain stimulation electrodes, biopsy needles, and the infusion of pharmaceuticals and laser catheters directly into the brain. ClearPoint Neuro also offers the ClearPoint Neuro Navigation System, an MRI suite designed to optimize the surgical environment. The company has established strategic license and collaboration agreements with prominent entities such as Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco, expanding its technological capabilities and market reach. ClearPoint Neuro's technology aims to improve patient outcomes by providing surgeons with real-time visualization and precise control during complex neurosurgical interventions.

What Products and Services Does CLPT Offer?

• Develops and commercializes platforms for minimally invasive surgical procedures in the brain.
• Offers the ClearPoint system for inserting deep brain stimulation electrodes and biopsy needles.
• Provides solutions for the infusion of pharmaceuticals and laser catheters into the brain.
• Offers the ClearPoint Neuro Navigation System, an MRI suite for enhanced surgical guidance.
• Enables surgeons to perform procedures under direct, intra-procedural MRI guidance.
• Collaborates with medical institutions and device manufacturers to expand technological capabilities.
• Aims to improve patient outcomes through precise and less invasive neurosurgical interventions.

How Does CLPT Make Money?

• Sales of ClearPoint system and related disposables.
• Revenue from ClearPoint Neuro Navigation System installations.
• Licensing and collaboration agreements with medical device companies.
• Service and maintenance contracts for installed systems.

What Industry Does CLPT Operate In?

ClearPoint Neuro operates within the medical device industry, specifically targeting the neurosurgery market. This sector is characterized by continuous innovation, driven by the need for more precise and less invasive surgical techniques. The market is competitive, with established players and emerging companies vying for market share. ClearPoint Neuro differentiates itself through its MRI-guided platform, which offers real-time visualization and enhanced precision. The global neurosurgery devices market is expected to grow, driven by an aging population, increasing prevalence of neurological disorders, and technological advancements. ClearPoint Neuro is positioned to capitalize on these trends by expanding its product offerings and strengthening its partnerships.

Who Are CLPT's Key Customers?

• Hospitals and medical centers performing neurosurgical procedures.
• Neurosurgeons specializing in deep brain stimulation, biopsy, and drug delivery.
• Research institutions conducting clinical trials and studies.
• Medical device companies integrating ClearPoint technology into their products.

ClearPoint Neuro, Inc. (CLPT) Valuation Context

Valued at $456M, CLPT is classified as a small-cap stock. Relative to its peer group, CLPT's quantitative score of 15/100 is below the peer average of 78/100.

CLPT Revenue & Earnings Trend

In Q2 2026, CLPT generated $10.9M in top-line revenue, marking a sequential decrease of 10.3%. The company recorded a net loss of $11.3M, with diluted EPS of $-0.38. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, CLPT averaged $-0.29 in diluted EPS.

Company Profile

ClearPoint Neuro, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Solana Beach, US. The company is led by CEO Joseph Michael Burnett. CLPT has traded publicly since 2012.

Key Financial Metrics

Return on assets is -31.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.79 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.5%, the inverse of the P/E and a quick read on earnings relative to price.

ClearPoint Neuro, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.23 places it in the distress zone, a signal of elevated financial risk.

ClearPoint Neuro, Inc. has missed Wall Street's EPS estimate in 8 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 20.7% below estimates on average.

Wall Street analysts project ClearPoint Neuro, Inc. revenue of about $48.9M for fiscal 2026, with EPS near $-1.32.

CLPT Financials

CLPT Latest News

CLPT Analyst Consensus

CLPT MoonshotScore

What Investors Ask About ClearPoint Neuro, Inc. (CLPT) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources